| abstract |
The present invention relates to keloid derived precursor cells (KPCs), which exhibit clonogenicity, self-renewal, distinct embryonic and mesenchymal stem cell surface markers, and multipotent differentiation. More specifically, the invention provides methods of utilizing KPCs for the generation of a human keloid-like tumor model, which allows for testing of the anti-tumor therapeutic effect of antibodies targeting distinct niche components, such as IL-6 and IL-17. |